Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases

Lancet

Volumn 351, Issue 9120, 1998, Pages 1905-1910

  Grob, Jean Jacques ^a   Dreno, Brigitte ^b   De La Salmonière, Pauline ^c   Delaunay, Michèle ^d   Cupissol, Didier ^e   Guillot, Bernard ^f   Souteyrand, Pierre ^g   Sassolas, Bruno ^h   Cesarini, Jean Pierre ⁱ   Lionnet, Sylvie ^j   Lok, Catherine ^k   Chastang, Claude ^c   Bonerandi, Jean Jacques ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b HÔTEL DIEU   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e CENTRE VAL D AURELLE   (France)

^f DEPARTMENT OF NEUROLOGY   (France)

^g HÔTEL DIEU   (France)

^h CHU MORVAN   (France)

ⁱ FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FEMALE; HEADACHE; HIGH RISK PATIENT; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; THICKNESS; VERTIGO; VOMITING;

EID: 7144228601     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)12445-X     Document Type: Article

References (13)

1. 1 Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75: 726-34.
2. 2 Balch CM, Buzaid AC. Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol 1996; 14: 1-3.
3. 3 Kirkwood J, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2 b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
4. 4 Kirkwood J. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18 (suppl 7): 83-90.
5. 5 Cascinelli N. Evaluation of efficacy of adjuvant therapy with IFN-alpha 2a in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 1995; 14: 410 (abstr).
6. 6 Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa 2 a in selected patients with malignant melanoma. J Clin Oncol 1995; 13: 2776-83.
7. 7 Slinghuff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Cancer 1992; 70: 1917-27.
8. 8 Balch CM, Soong SJ, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous melanoma, 2nd edn. New York: J B Lippincott, 1992: 165-87.
9. 9 Whitehead J. The design and analysis of sequential clinical trials, 2nd edn. New York: Ellis Horwood, 1992.
10. 10 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958; 53: 457-81.
11. 11 Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
12. 12 Balch CM, Cascinelli N, Drzewieecki KT, et al. A comparison of prognostic factors worldwide. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous melanoma, 2nd edn. New York: J B Lippincott, 1992: 188-99.
13. 13 Cascinelli N, Bufalino R, Morabito A. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343: 913-14.